Impact of Impella 5.5 on heart function in adults with end-stage heart failure

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, single-center observational study evaluating how Impella 5.5 affects both left and right ventricular function in adults with end-stage heart failure. Researchers will measure heart strains, myocardial work, standard echocardiographic metrics, and hemodynamics at baseline, immediately after device start, and up to 14 days after implantation. Data collection includes echocardiographic imaging and related clinical information, with some imaging obtained for research alongside routine care. The study does not modify patient management, and additional imaging may be performed for research purposes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Adult patients over 18 years old
2. Require Impella 5.5 implantation

Exclusion Criteria:

1. Patients' inability to provide consent for themselves (including that patients' lack of understanding the research)
2. Any patients who are deemed at higher-than-normal risk for complications secondary to echocardiography, such as dysphagia or esophageal pathology

Where it's running

• University of Rochester Medical Center
  Rochester, New York, United States Recruiting

Study contacts

• Study coordinator: Yoshihisa Morita
• Email: yoshihisa_morita@urmc.rochester.edu
• Phone: 585-275-2141

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Long-term outcomes after LVAD implantation for end-stage heart failure

  We will follow adults with end-stage heart failure who get an LVAD to see if they live longer and to record complications and hospital visits over the next 3–5 years.

  Recruiting The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Nanjing, Jiangsu · NCT07382284

• Comparing LVAD and medical therapy for advanced heart failure patients

  This study tests whether the HeartMate 3 device can help people with severe heart failure feel better and live healthier lives compared to standard medical treatments.

  Recruiting at 8 sites Hospices Civils de Lyon · Besançon and 7 other locations · NCT04768322

• Noninvasive monitoring of heart function in patients with LVADs

  This study is testing new ways to monitor heart function in people with a HeartMate 3 LVAD to see if they can get better information than the usual methods like echocardiograms and ECGs.

  Recruiting Medical University of Vienna · Vienna · NCT04641416

• Heart transplants from HIV-positive donors for HIV-positive recipients

  This study is testing if heart transplants from both HIV-positive and HIV-negative donors are safe and effective for people living with HIV.

  Recruiting University of Texas Southwestern Medical Center · Dallas, Texas · NCT06659952

• Personalized High-Rate Fluid Removal Guided by Ultrasound in Hospitalized ESRD with Fluid Overload

  This trial tests whether using ultrasound to guide a higher rate of fluid removal is as safe and effective as standard fluid removal for adults with end-stage kidney disease who are admitted for severe fluid overload.

  Recruiting Universidad Autonoma de Nuevo Leon · Monterrey, Nuevo León · NCT07705269

• Choosing dialysis: what matters most to patients

  This project uses a questionnaire to see which factors, including possible financial compensation, influence dialysis choices among adults with advanced kidney failure who are considering dialysis options.

  Recruiting at 2 sites University Hospital, Caen · Caen and 1 other locations · NCT07535320

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.